Although major advances have been achieved in the treatment of ER-positive or HER2-amplified breast cancers, there are no clinically targeted therapies for TNBC, thus leaving cytotoxic chemotherapy as the only choice for systemic therapy [8]. Here, ERBB2 is linked to breast carcinoma.